Brief: Royalty Pharma Q1 net income USD 509 million
09/05/2023 12:59
May 9 (Reuters) - Royalty Pharma Q1 adjusted EBITDA USD 1,044 million. * Q1 pretax profit USD 509 million * Q1 net income USD 509 million * Q1 operating expenses USD 205 million * Q1 operating income USD 479 million
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)